Skip to main content

Table 3 Number of patient blood draws per treatment modality and visit

From: Longitudinal autoantibody responses against tumor-associated antigens decrease in breast cancer patients according to treatment modality

Treatment Groupa Baseline 6 Month 12 Month Subtotal
Radiation + Hormonal 59 (29.5%) 52 52 163
Hormonal 31 (15.5%) 25 26 82
Radiation + Hormonal + Chemotherapy 25 (12.5%) 23 22 70
Surgery Only 24 (12.0%) 15 10 49
Hormonal + Chemotherapy 15 (7.5%) 12 13 40
Radiation 13 (6.5%) 8 8 29
Radiation + Chemotherapy 11 (5.5%) 11 11 33
Radiation + Hormonal + Chemotherapy + Trastuzumab 8 (4.0%) 8 8 24
Chemotherapy 5 (2.5%) 4 5 14
Hormonal + Chemotherapy + Trastuzumab 5 (2.5%) 5 5 15
Radiation + Chemotherapy + Trastuzumab 3 (1.5%) 2 2 7
Radiation + Hormonal + Trastuzumab 1 (0.5%) 1 1 3
Total number of samples 200 (100%) 166 163 529
  1. aAll patients received surgery to remove the primary tumor